MEDICAMEQ302.00

Medicamen Biotech Limited

· Pharma & Health
₹ CrorePeersMEDICOAAREYDRUGSNECLIFEHALEOSLABSALBERTDAVDNATCAPSUQVALIANTLABBALPHARMAMcap ₹410 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
MEDICAMEQ
FY26
MEDICO
FY26
AAREYDRUGS
FY26
NECLIFE
FY26
Peer
Median
Valuation — at last close
P/E41.83×22.15×68.34×45.25× -8%
P/B1.49×0.00×1.80×0.40×0.40× +274%
EV/EBITDA21.75×0.89×44.46×-3.59×0.89× +2340%
Market Cap₹410 Cr₹0.1 Cr₹270 Cr₹231 Cr₹231 Cr +77%
Growth
Revenue CAGR 3Y11.97%13.69%96.26%-81.73%13.69% -13%
Revenue CAGR 5Y-64.04%-64.04%
Net Income CAGR 3Y-12.71%21.89%100.20%61.05% -121%
Revenue YoY (latest Q)11.27%81.43%-56.34%-99.99%-56.34% +120%
Net Income YoY (latest Q)15.35%38.49%-25.36%75.65%38.49% -60%
Profitability
EBITDA Margin9.90%8.25%1.52%4.88% +103%
Net Income Margin4.95%6.35%0.84%-3152.45%0.84% +489%
Return on Common Equity3.50%17.38%2.64%-50.30%2.64% +33%
Return on Capital Employed4.35%18.39%2.84%-10.25%2.84% +53%
Return on Assets2.63%8.55%1.33%-47.12%1.33% +98%
Credit & Quality
Total Debt/Equity0.17×0.25×0.33×0.00×0.25× -32%
Interest Coverage3.54×7.71×0.86×-1.69×0.86× +312%
Scale — latest FY
Revenue / Total Income₹198 Cr₹206 Cr₹472 Cr₹0 Cr₹206 Cr -4%
Net Income₹9.8 Cr₹13.1 Cr₹4 Cr−₹293 Cr₹4 Cr +147%
Total Assets₹372 Cr₹153 Cr₹297 Cr₹622 Cr₹297 Cr +25%
EPS₹7.22₹1.58₹1.39₹-13.4₹1.39 +419%
Book Value per Share₹203.17₹26,774.83₹52.86₹29.97₹52.86 +284%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.